• MASTER-2 (Relapsing MS Trial)

Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03933202

 

  • CLICK-MS (Relapsing MS Trial)

Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03933215

 

  • GEMINI2 – EFC 16034

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio┬«) in Participants With Relapsing Forms of Multiple Sclerosis – To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04410991?titles=GEMINI2

 

  • PERSEUS – EFC 16035

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) – To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04458051?titles=PERSEUS